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ABSTRACT 
Objectives: To assess the frequency of resistance of Mycobac- 
terium tuberculosis to antituberculosis drugs and the factors 
associated with it among patients with tuberculosis (TB) and 
acquired immunodeficiency syndrome (AIDS). 
Materials and Methods: The medical records of TB and AIDS 
cases diagnosed from 1992 to 1997 in a public service for 
AIDS care were reviewed. 
Results: Resistance was diagnosed in 82 (19%) of 431 cases. 
The mean and median values between the diagnosis of AIDS 
and the diagnosis of TB were 214.8 days and 70.5 days, 
respectively. Multidrug-resistant TB (MDR TB) occurred in 
11.3% of cases. Of the 186 patients with no previous treatment, 
13 (6.9%) presented primary MDR TB. Of the 90 cases with 
previous treatment, six (6.7%) presented monoresistance to 
rifampin and 27 (30%) presented MDR TB. The distribution of 
cases with sensitive and resistant M. tuberculosis strains was 
homogeneous in terms of the following variables: gender, age, 
category of exposure to human immunodeficiency virus (HIV), 
alcoholism, and homelessness. Multivariate analysis showed 
an association between resistance and the two following vari- 
ables: previous treatment and duration of AIDS prior to TB 
exceeding 71 days. The rates of primary multiresistance and 
of monoresistance to rifampin were higher than those detected 
in HIV-negative patients in Brazil. 
Conclusions; In this patient series, M. tuberculosis resistance 
was predominantly of the acquired type, and resistance was 
independently associated with previous treatment for TB and 
with duration of AIDS prior to TB exceeding 71 days. 
Key Words: AIDS, Brazil, drug resistance, HIV infection, MDR 
TB, rifampin monoresistance, multidrug resistance, 
tuberculosis 
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Over the past few years, the drug resistance of Mycobac- 
terium tuberculosis in patients with acquired immun- 
odeficiency syndrome (AIDS) has become a topic of 
international interest, especially after the occurrence of 
hospital outbreaks of multidrug-resistant tuberculosis 
(MDR TB) in the United States.’ Some studies have 
detected a higher prevalence of resistance in patients 
with AIDS than in human immunodeficiency virus @Irv>- 
negative patients,2-4 whereas other studies have not 
detected this associatiom5-* This diversity of results may 
be attributable to differences in the epidemiologic situa- 
tion of TB in different places and to differences in the 
model of care provided to patients with TB or AIDS. In 
Brazil, few studies have evaluated resistance to anti-tuber- 
culosis drugs in patients with AIDS.9-‘1 Co-infection with 
TB and HIV is of special relevance in the State of Slo 
Paulo, where the cumulative incidence of AIDS from 1980 
to 1998 was 211.7 cases per 100,000 inhabitants and 
where TB was recorded in 33% of adult patients with 
AIDS.12,” On the basis of clinical radiographic or micro- 
biologic data, 919 cases of coinfection with TB and AIDS 
were reported to the Reference and Training Center for 
Sexually Transmitted Diseases and AIDS (STD/AIDS) 
(CRTA-SP) in the city of SZo Paulo from 1993 to 1997 
(Epidemiological Surveillance Service of CRTA. Personal 
communication). Since 1992, susceptibility tests have 
been performed in all cases of positive culture and iden- 
tification of ~$4, tuberculosis at the Center. The present 
report is a review of the experience of this reference 
public service for AIDS care (CRTA-SP) in terms of cer- 
tain aspects of antituberculosis drug resistance in patients 
with AIDS. 
MATERIALS AND METHODS 
The cases were selected by a survey of the records of 
the Adolf0 Lutz Institute (IAL) referring to patients of 
the CRTA-SP whose strains were isolated and identified 
as M. tuberculosis from January 1992 to June 1997 and 
had been submitted to susceptibility tests. Individuals 
with a positive anti-HIV test (by enzyme-linked 
immunosorbent assay [ELISA] and Western blot) and 
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with clinical signs and symptoms of AIDS according to 
the 1992 criteria of the Health Ministery and of the Cen- 
ters for Disease Control and Prevention (CDC) were 
included in the study. *4x15 The patients’ medical records 
were reviewed and adapted to a standardized form. The 
following data were recorded: gender, age, date at TB 
diagnosis (date of collection of the first specimen from 
which M. tuberculosis was identified and which was 
submitted to the susceptibility tests), date of AIDS diag- 
nosis, category of exposure to HIV infection, history of 
alcoholic drink consumption, homelessness, treatment 
with antituberculosis drugs, clinical form (considering 
the origin of M. tuberculosis-positive specimens), the 
number of days the patient had AIDS prior to tubercu- 
losis, follow-up time, and survival. The laboratory tests 
for TB investigation were requested at the outpatient 
clinic, the day hospital, and the ward of the CRTA dur- 
ing routine visits and were performed in the laborato- 
ries of CRTA-SP and IAL. The susceptibility tests were all 
performed at IAL, based on the proportion method and 
on the resistance ratio method.‘6~‘7 Using the propor- 
tion method, strains were considered to be resistant 
when they presented growth at the proportion of 1% or 
more in tubes containing the following drug concen- 
trations: isoniazid (H), 0.2 pg/mL; rifampin (R), 40.0 
kg/mL; streptomycin (S), 4.0 kg/mL; ethambutol (E), 2.0 
kg/mL; and 10% growth with 100 pg/mL pyrazinamide 
(2)‘” Using the resistance ratio method, the strains were 
considered to be resistant to H, R, S, or E when they 
grew in tubes containing drug concentrations that 
resulted in ratios of 4:l or more compared to the con- 
centrations in the control tubes. Strains were consid- 
ered to be resistant to pyrazinamide when they grew in 
tubes containing this drug at the concentration of 200 
pg/mL. Primary resistance (PR), acquired resistance 
(AR), and MDR TB (characterized by resistance to at 
least isoniazid and rifampin) were defined according to 
the criteria of the World Health Organization.18 In cases 
in which no information was available about previous 
treatment, resistance was classified as “indeterminate 
resistance” (IR). 
Simple linear regression was used for the analysis of 
the tendency of resistant cases over time. The series was 
stratified into two groups: patients with strains sensitive 
to all drugs tested and patients with strains resistant to 
one or more drugs. The possibility of correlation between 
M. tuberculosis resistance and other variables was stud- 
ied by univariate analysis, using the chi-squared and odds 
ratio tests to determine the presence of significant asso- 
ciations (P < 0.05). The logistic regression model was 
used for the multivariate analysis test, considering the 
occurrence of resistance as the dependent variable and 
all variables that had been associated with resistance in 
univariate analysis at P < 0.20 as independent variables.‘” 
TO assess the survival time of patients with sensitive 
strains and those with resistant ones, the initial time was 
considered to be the date of collection of the first 
specimen from which M. tuberculosis was isolated and 
submitted to the susceptibility tests (date of TB diagno- 
sis). The date of death was recorded, and for the patients 
who did not die,the time of observation was considered 
(i.e., the follow-up time until the last medical visit during 
the study period, which was concluded on June 30,1997X 
The same procedure was used with the date of AIDS 
diagnosis considered to be the initial time. The micro- 
computer Stata statistical software 4.0 (Statacorp, College 
Station, Texas, USA) was used. 
RESULTS 
Tests of susceptibility of the M. tuberculosis strains iso- 
lated from the specimens obtained from 452 patients 
were performed during the study period. Twenty-one of 
these patients were excluded from analysis, three 
because of negative anti-HIV serology and 18 because 
of the lack of information in their medical records. Thus, 
the study was conducted on 431 patients with TB and 
AIDS. Age ranged from 16.3 years to 66.3 years (mean = 
33.6 y; median = 32.5 y), and 368 subjects (85.4%) were 
males. With respect to the categories of exposure to HIV 
there was a predominance of homosexuals (35.7%) and 
of drug users (32.5%). The most frequent clinical form 
was the pulmonary form (58.0% of cases), followed by 
the disseminated form (20.0%) and the lymphatic form 
(16.2%). In 307 patients (71.2%) there was pulmonary 
involvement, in 101 (23.4%) there was lymphonodal 
involvement, in 28 (6.5%) meningeal involvement, and in 
23 patients (5.3%) lesions in other organs or systems 
were diagnosed separately (renal, pleural, pericardic, cuta- 
neous, and testicular TB) or in parallel to pulmonary, 
lymphonodal, and meningeal lesions (disseminated 
forms). Previous treatment for TB was reported by 90 
patients (20.9%) was denied by 186 (43.2%) and for 155 
patients (36.0%) there was no information about this 
variable; 72 (16.7%) patients reported alcohol con- 
sumption and 30 (7.0%) were homeless. Among the 431 
patients, the time elapsed between the diagnoses of AIDS 
and TB was not available for nine. Taking into account 
this time, the other 422 patients were divided in three 
groups. At first, based on the median value of this sam- 
ple, the patients were divided in two groups: 211 with 
less than 71 and the others with more than 71 days. This 
second group was again divided in two groups based 
on the median value of 241 days. A total of 395 patients 
(91.6%) were followed-up for a period ranging from 1 to 
1832 days (5 y) and 36 cases (8.4%) were lost to follow- 
up after the diagnosis of TB. 
In 82 cases (19.0%) the M. tuberculosis strains were 
resistant, 31 of them (7.2%) being monoresistant and 51 
(11 .S%) being resistant to two or more drugs. Monore- 
sistance corresponded to 2.6% of resistance to H, 2.1% to 
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Table 1. Distribution of 82 Cases of TB Caused by Resistant Mycobacterium tuberculosis in Relation to the Total Series of 431 Cases, 
according to the Type of Resistance to Antituberculosis Drugs* 
Type of Resistance 
H 
R 
2 
S 
H, R 
H, R Z 
H, R, E 
H, R, S 
H, R, Z, E, S 
H Z 
H, Z, E 
AR 
n = 37 (8.5%) 
1 (0.2) 
6 (1.4) 
3 (0.7) 
0 C-J 
18 (4.2) 
7 (1.6) 
7 (0:;; 
1 (0.2) 
PR IR 
n = 24 (5.5%) n = 21 (4.8%) 
5 (1.2) 5 (1.2) 
1 (0.2) 2 (0.5) 
0 c-1 2 (0.5) 
4 (0.9) 2 (0.5) 
12 (2.8) 4 (0.9) 
1 (0.2) 4 (0.9) 
0 i-i 1 (0.2) 
0 (4 0 C-1 
7 CO!;; ; ;I; 
0 l-3 1 (0.2) 
Total 
n = 82 (19.0%) 
11 (2.6) 
9 (2.1) 
5 (1.2) 
6 (1.4) 
34 (7.9) 
12 (2.8) 
1 (0.2) 
1 (0.2) 
1 (0.2) 
1 (0.2) 
1 (0.2) 
*CRTA-SP 1992-l 997. 
AR = acquired resistance; PR = primary resistance; IR = indeterminate resistance; H = isoniazid; R = rifampin; Z = pyrazinamide; S = sbpbnycin; E = &ambub 
R, 1.2% to 2, and 1.4% to S; resistance to the H-R combi- 
nation was the most frequent type of multiresistance, 
occurring in 34 (7.9%) cases. In the total series, the 
frequency of AR (8.5%) was higher than the frequency of 
PR (5.5%), with acquired monoresistance in 2.3%, 
acquired multiresistance in 6.2%, primary monoresistance 
in 2.3%, and primary multiresistance in 3.2% of cases. In 
the cases monoresistant to S, there was a predominance 
of PR, and in the cases monoresistant to R, there was a 
predominance of AR. Resistance to at least the H-R com- 
bination was observed in 49 patients (11.3%), being char- 
acterized as AR in 6.2% (27/431), PR in 3.0% (13/431), and 
IR in 2.0% (9/431) of cases. The rates of primary monore- 
sistance to H (1.2%) and to S (0.9%) were similar to one 
another and higher than those observed for R (0.2%). No 
primary resistance to E was observed (Table 1). Infor- 
mation about the previous use of antituberculosis drugs 
was obtained for 64% (276/431) of the patients. Of the 
90 patients who reported previous use of these drugs, 37 
(41.1%) presented AR; of the 186 patients with no pre- 
vious treatment, 24 (12.9%) presented PR (Table 2). Sim- 
ple linear regression analysis among the variable number 
of individuals with multiresistant M tuberculosis and year 
of diagnosis revealed no trends toward an increase or a 
decrease in the number of resistant cases (t = -0.31, P = 
0.774) during the study period. 
There was no significant difference between the 
patient group with sensitive strains and the group with 
resistant ones with respect to the distribution of cases of 
the pulmonary, lymphatic, and disseminated forms of TB 
(x2= 4.33; P = 0.11). 
There was no significant difference between patient 
groups with sensitive and resistant strains in terms of 
patient distribution by gender (x2 = 1.917; P = 0.166), age 
range (x2 = 5.999; P = 0.112), category of exposure to HIV 
infection (x2 = 3.986; P = 0.408), a history of alcohol con- 
sumption (x2 = 3.295; P = 0.070), or homelessness (x2 = 
2.579; P = 0.108). The proportion of patients submitted 
to previous treatment was significantly higher in the 
patient group with resistant strains (x2 = 28.03; P < 0.001). 
For the comparison of patient groups with sensi- 
tive and resistant strains in relation to the time elapsed 
between the diagnoses of AIDS and TB, the median val- 
ues of 71 and 241 days were considered as limits. These 
Table 2. Distribution of 431 Cases of Co-infection with TB and AIDS, according to Profile of Sensitivity to 
Mycobacterium tuberculosis and a History of Previous TB Treatment* 
With Treatment Without Treatment 
Sensitivity Profile n = 90 (700%) n = 186 (100%) 
Sensitive 53 (58.9) 162 (87.1) 
Resistant 37 (41 .l) 24 (12.9) 
H 1 (1.1) 5 (2.7) 
R 6 (6.7) 1 (0.5) 
Z 3 (3.3) 0 (0.0) 
S 0 (0.0) 4 (2.2) 
H, R 18 (20.0) 12 (6.4) 
H, R Z 7 (7.8) 1 (0.5) 
H, R E 0 (0.0) 0 (0.0) 
H, R S 1 (1.1) 0 (0.0) H, R, Z, E, S  ( . ) 0 (0.0) 
H, Z 0 (0.0) 1 (0.5) 
H, Z E 0 (0.0) 0 (0.0) 
*CRTA-SP 1992-l 997. 
H = isoniazid; R = rifampin; Z = pyrazinamlde; S = streptomycin; E = ethambutol. 
No information 
n = 755 (700%) 
134 (86.5) 
21 (13.5) 
5 (3.2) 
2 (1.3) 
2 (1.3) 
2 (1.3) 
4 (2.6) 
4 (2.6) 
1 (0.6) 
0 (0.0)  ( . ) 
0 (0.0) 
1 (0.6) 
Total 
n = 437 (700%) 
349 (80.97) 
82 (19.0) 
11 (2.6) 
9 (2.1) 
5 (1.2) 
6 (1.4) 
34 (7.9) 
12 (2.8) 
1 (0.2) 
: ii:;; 
1 (0.2) 
1 (0.2) 
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Variable 
Table 3. Univariate Analysis of the Correlation between Resistance and the Other Variables 
Patient Groups 
95% Confidence 
RG SG Odds Ratio interval X’ P-Value 
Previous treatment 
No(n= 186) 24 
Yes (n = 90) 37 
Duration of AIDS prior to TB* 
< 71 d (n = 211) 20 
71-241 d(n =106) 23 
> 241 d (n = 105) 39 
Alcohol consumption 
No (n = 201) 38 
Yes (n = 72) 21 
Homeless 
No (n = 398) 72 
Yes (n = 30) 9 
Age (Y) 
~25 (n = 46) 10 
25-35 (n = 242) 45 
36-45 (n = 114) 17 
>46 (n = 29) 10 
Gender 
Male (n = 368) 74 
Female (n = 63) 8 
162 
53 4.71 2.60-8.55 28.03 0.000 
191 1 
83 2.65 
66 5.77 
163 
51 
326 1 
21 1.94 
36 
197 
97 
19 
0.82 0.38-1.78 
0.63 0.26-1.51 
1.89 0.67-5.35 6.0 0.112 
294 1 
55 0.58 
1.77 0.96-3.27 3.29 0.070 
1.39-5.05 
3.00-l 1.13 34.74 0.000 
0.87-4.34 2.58 0.108 
0.27-1.25 1.92 0.1662 
*Average number of days in the 3 groups: 3.5, 156.5, 1342.5 
RG = resistant strains: SG = sensitive strains. 
values delimited three groups of patients who had on 
average 35.0, 156.5, and 1342.5 days of AIDS evolution 
at the time of TB diagnosis. The proportion of patients 
with duration of AIDS prior to TB exceeding 71 days 
was significantly higher in the patient group with resis- 
tant strains (x2 = 34,74; P < 0.001). Multivariate analy- 
sis showed an increased chance of drug resistance 
among patients with previous treatment and among 
those with a time of AIDS evolution exceeding 71 days 
(Tables 3 and 4). 
Survival among the patient group with resistant 
strains was lower than that of those with sensitive ones, 
with a significant difference (P < 0.01) when the patients 
with sensitive strains were compared to patients with TB 
caused by monoresistant and multiresistant M. tubercu- 
losis. The median survival time after the diagnosis of TB 
was 434 days for the patient group with sensitive strains, 
251 days in cases with monoresistance, and 100 days in 
cases with multiresistance. There was no significant dif- 
ference (P = 0.74) in survival time after the diagnosis of 
AIDS between the two patient groups. 
DISCUSSION 
The presence of some type of resistance in 19% of these 
patients demonstrates the relevance of this problem in 
the present series. Case distribution by gender, age range, 
and category of exposure to HIV was close to that 
recorded for AIDS cases during the same period in the 
state and in the municipality of Sao Paulo.20 The fre- 
quency of 58% for the isolated pulmonary form and of 
71.2% for pulmonary involvement as well as the fre- 
quency of the lymphatic and localized forms were simi- 
lar to those observed in other studies.21-2” 
Tuberculosis occurred within the first 2 to 3 months 
after the diagnosis of AIDS in 50% of cases and within up 
to 8 months in 75% of cases, showing that TB occurs 
early in relation to other opportunistic infections in most 
patients with AIDS.25-28 The survival of approximately 14 
months after the diagnosis of TB in the patient group 
with sensitive strains was lower than that observed in 
other countries.29 Although, resistance is considered to 
have played a role in reducing the survival; the magnitude 
Table 4. Analysis of the Correlation between Resistance and the Remaining Variables* 
Variable Odds Ratio 95% Confidence /nten/al Z 
Previous treatment 
No 1 
Yes 3.396 1.740-6.629 3.585 
Duration of AIDS prior to TB 
<71 d 1 
71-241 d 2.883 1.213-6.854 2.397 
>241 d 4.348 1.96s9.641 3.617 
*Results of multlvariate analysis, final model. 
P-Value 
0.000 
0.017 
0.000 
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of other important factors related to this issue could not 
be evaluated. There was a lack of information about treat- 
ment adherence and the immunologic status of the 
patients (CD4 cell count). 
When the types of resistance were compared to those 
observed in surveys carried out in different parts of the 
world, no substantial differences were observed.3u The AR 
rate was higher than the PR rate, multiresistance was more 
frequent as AR than as PR, the rates of primary monore- 
sistance to H and S were similar to each other and higher 
than those observed for R, and primary monoresistance to 
E was absent. However, there was a high frequency of 
monoresistance to R, a feature not observed among the M. 
tuberculosis strains isolated in Brazil.” 
Most cases with strains monoresistant to R were clas- 
sified as cases of AR, as also reported in the literature.“2-35 
Brazilian studies in which M. tuberculosis susceptibility 
was assessed in HIV-infected patients dealt with signifi- 
cantly smaller patient series and did not mention the cri- 
teria used for patient selection,‘“,” thus preventing 
comparison with the present series. 
The percentage of primary multiresistance was 
higher than the values reported for HIV-negative patients 
in Sao Paul0 and in other parts of Brazil.31~36 The rates of 
primary resistance to each drug were higher for H and 
R, lower for S, and similar for E when compared with 
those obtained in a recent Brazilian survey.“’ The fre- 
quency of acquired multiresistance was also higher than 
that observed in the same survey. 
A high prevalence of primary resistance to the H-R 
combination has been reported for HIV-positive patients 
in other countries.* In the present study, 6.9% of previ- 
ously untreated patients presented primary multiresis- 
tance. This highly significant value may be explained by 
the nosocomial transmission of multiresistant strains, 
although there are no reports of nosocomial outbreaks of 
MDR TB in the country. 
It is important to emphasize the greater use of day- 
hospital beds and of wards for the care of these patients 
during the period of specimen collection in the present 
study, which preceded the recent phase of reduction in 
AIDS morbidity attributed to combined antiretroviral ther- 
apy.“’ It is also important to point out the possibility of 
transmission in outpatient clinics or in the community. 
No correlation was detected between AR and fac- 
tors considered to predispose to treatment default, such 
as drug dependence.38 The absence of a correlation 
between resistance and homelessness may be explained 
by the fact that most homeless patients were not street 
dwellers but patients sheltered in care facilities. Thus, it 
can be seen that, although the proportion of patients 
with previous treatment was significantly higher among 
those who presented resistance, it was not possible to 
identify, in these cases, factors other than treatment itself 
as being correlated with resistance. The possibility should 
also be considered that some of these cases were attrib- 
utable to exogenous reinfection and, therefore, were cases 
of primary and not acquired resistance. Reinfection with 
resistant bacilli may occur during or after the treatment 
of TB caused by sensitive M. tuberculosis strains.39 These 
strains can only be differentiated using DNA fingerprint- 
ing methodology. This result indicates the need to rede- 
fine the concept of acquired resistance in patients with 
AIDS. Among patients in the present study, a longer dura- 
tion of AIDS prior to TB was significantly correlated with 
resistance, as also reported in the literature in some stud- 
ies of the case-control type in nosocomial outbreaks of 
MDR TB.40.41 Exogenous infection or reinfection with the 
development of primary progressive TB is usually asso- 
ciated with the most advanced phase of AIDS. In some 
studies there was a longer duration of AIDS prior to TB 
among patients with MDR TB compared to patients with 
susceptible TB, a fact that was not discussed by the 
authors.4”%“’ The relation between resistance, extent of 
immunosuppression, and HIV infection was indirectly 
suggested in a study on African patients with TB. In that 
series, there was a higher proportion of individuals with 
resistant strains among patients with CD4 lymphocyte 
counts lower than 200 cells/m3. In most of those cases, 
resistance was characterized as primary.” 
CONCLUSION 
The hypothesis should be considered that, as is the case for 
patients with AIDS in other countries, the group of patients 
with primary multiresistance in the present series con- 
tributed to the observed significant association between 
resistance and longer duration of AIDS prior to TB. 
There is the possibility that acquired resistance is 
more prevalent among patients in more advanced stages 
of AIDS owing to irregular treatment, either because of 
factors related to the attitude of patients with a long time 
of evolution or to the concomitance of upper digestive 
alterations, diarrhea, and malabsorption. 
The results of the susceptibility tests observed in 
these cases indicate the need to rediscuss the diagnostic 
and therapeutic approach to co-infected patients with 
TB and HIV The use of a four-drug schedule until the 
results of susceptibility tests are obtained could be eval- 
uated in a prospective study of patients with previous 
treatment and with a longer time of AIDS evolution. Fur- 
thermore, it is imperative to propose the validation of a 
predictive model for the occurrence of resistance in these 
patients. To obtain conclusive results, these cases should 
be extensively studied, with the identification of factors 
related to the psychosocial aspects of the patients as well 
as to the epidemiology and pathogenesis of co-infection 
with MDR TB and AIDS. Sequential immunologic evalua- 
tion will be needed for this program, as well as resources 
of molecular biology that will permit differentiation 
between primary and acquired resistance. 
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